Study results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as monotherapy

GLP-1RA attenuated myeloid expansion and inflammatory transcriptional responses, whereas LD-IL2 increased Treg numbers and transcripts associated with Treg stability and suppressive function

Coya believes findings support further evaluation of COYA 303 and combination approaches in addressing Alzheimer’s disease and other complex neurodegenerative indications

Coya will continue to pursue non-dilutive avenues and potential partnerships to advance the COYA 303 program

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic applications of GLP-1 receptor agonists across diverse disease settings, including their emerging immunomodulatory effects.

COYA 303 is a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 receptor agonist (GLP-1RA), and was evaluated in a subacute low-dose lipopolysaccharide (LPS) mouse model. The LPS mouse model recapitulates key features relevant to neurodegenerative diseases, including increased pro-inflammatory signaling and myeloid activation, leading to immune dysregulation, providing a validated setting for testing potential therapeutic interventions. The study evaluated whether simultaneously attenuating inflammatory myeloid activity and reinforcing Treg-mediated immune regulation could produce broader immunomodulatory effects than either approach alone.